Most Read Articles
Pearl Toh, 2 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
5 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Pulmonary artery enlargement during AE of f-ILD predicts poor survival outcome

27 Jul 2019

A pulmonary artery diameter to ascending aorta diameter ratio (PA/A) ≥1 during acute exacerbation (AE) is a predictor of poor survival outcomes in patients with fibrotic interstitial lung disease (f-ILD), suggest the results of a recent study.

“To the best of our knowledge, this is the first longitudinal examination of the PA/A ratio and evaluation during AE of f‐ILD,” the investigators claimed.

Forty-five of the 123 patients included had PA/A ≥1 during AE. Compared to the PA/A <1, these patients were younger, had lower % vital capacity (VC) and % forced vital capacity (FVC), required more long-term oxygen therapy and other treatment, and had lower PaO2/FiO2 (P/F) ratios.

PA/A during AE increased compared with that during stable periods (p<0.001). Moreover, PA/A ≥1 significantly correlated with 90-day mortality both before and after adjustment for age, the P/F ratio at admission, long-term oxygen therapy usage and the type of background f-ILD (p=0.018 and 0.025).

This study included patients with a diagnosis of AE of f-ILD and with a computed tomography (CT) scan performed during stable period to confirm background fibrosis, as well as a CT scan at admission. CT during and prior (when available) to AE were used to measure the pulmonary arterial diameter, ascending aortic diameter and PA/A so as to assess the changes. Demographic data, comorbidities and clinical outcome (90-day mortality) were analysed.

“In f‐ILD, PA/A ≥1 during the stable stage is associated with worse outcomes,” the investigators noted, “[but] the effect of AE on the PA/A is unknown.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
5 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.